You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

polyadenosine 5'diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer Trial in Baltimore (Olaparib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022

Ovarian Cancer Trial in Worldwide (Olaparib, Ceralasertib, Placebo to match olaparib)

Withdrawn
  • Ovarian Cancer
  • Anchorage, Alaska
  • +25 more
Mar 9, 2021

Prostatic Tumors Trial in Worldwide (Pembrolizumab, Olaparib, Abiraterone acetate)

Active, not recruiting
  • Prostatic Neoplasms
  • Pembrolizumab
  • +4 more
  • Fullerton, California
  • +192 more
Oct 17, 2022

Lung Tumors, NSCLC Trial in Worldwide (biological, drug, radiation)

Recruiting
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Pembrolizumab
  • +9 more
  • Mobile, Alabama
  • +194 more
Aug 18, 2022

Breast Cancer Trial in Boston (Talazoparib, Sacituzumab Govitecan)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +1 more
Jan 6, 2023

Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)

Active, not recruiting
  • Metastatic Breast Cancer
  • PARP inhibitor 2X-121
  • Herlev, Denmark
  • +1 more
Feb 1, 2023

Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Tumors Trial in France, Spain, United Kingdom (Niraparib, Dostarlimab)

Recruiting
  • Neoplasms
  • Brno, Czechia
  • +20 more
Nov 21, 2022

Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphoid System Tumor, Malignant Solid Tumor Trial run by the National Cancer

Recruiting
  • Adrenal Gland Pheochromocytoma
  • +3 more
  • Computed Tomography
  • +2 more
  • Bethesda, Maryland
  • +1 more
Jan 3, 2023

Metastatic Cancer, Unspecified Adult Solid Tumor Trial in Los Angeles (PARP inhibitor BMN-673, temozolomide, irinotecan HCl)

Completed
  • Metastatic Cancer
  • Unspecified Adult Solid Tumor
  • PARP inhibitor BMN-673
  • +4 more
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center
Sep 22, 2022

Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer Trial in United States (CB-839, Talazoparib)

Terminated
Has Results
  • Solid Tumor
  • +6 more
  • Birmingham, Alabama
  • +8 more
Feb 16, 2022

Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer Trial (AsiDNA, Olaparib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • +2 more
  • (no location specified)
Jan 17, 2023

Breast Cancer Trial in Tucson (Rucaparib)

Active, not recruiting
  • Breast Cancer
  • Tucson, Arizona
    University of Arizona Cancer Center
Feb 24, 2022

Ovarian Tumors Trial in United States (Niraparib, Bevacizumab)

Active, not recruiting
Has Results
  • Ovarian Neoplasms
  • Mobile, Alabama
  • +27 more
Nov 23, 2022

Solid Tumors Trial in Worldwide (Tislelizumab, Pamiparib)

Completed
Has Results
  • Solid Tumors
  • Scottsdale, Arizona
  • +28 more
Oct 27, 2021

Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or

Recruiting
  • Ovarian Cancer
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Jul 13, 2022

    Ovarian Cancer Trial in Toronto (Cediranib, Olaparib)

    Completed
    • Ovarian Cancer
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    May 3, 2022

    Predictive Immune Biomarkers of Response to PAPR Inhibitors

    Recruiting
    • Ovarian Cancer
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Nov 25, 2022

      Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)

      Not yet recruiting
      • Metastatic Solid Tumor
      • +4 more
      • San Francisco, California
        University of California, San Francisco
      Jan 12, 2023

      Ovarian Cancer Trial (JPI-547)

      Not yet recruiting
      • Ovarian Cancer
      • (no location specified)
      Jul 24, 2022

      Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma

      Not yet recruiting
      • Anatomic Stage III Breast Cancer AJCC v8
      • +3 more
      • (no location specified)
      Jul 28, 2023

      Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors Trial in Guangzhou (Fluzoparib, Radioactive particle

      Recruiting
      • Sarcoma,Soft Tissue
      • +2 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      May 30, 2023

      Advanced Pancreatic Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 Trial in

      Recruiting
      • Advanced Pancreatic Carcinoma
      • +27 more
      • Gainesville, Florida
      • +3 more
      Jan 3, 2023

      Squamous Cell Carcinoma of Head and Neck Trial in Chapel Hill, Charleston (biological, drug, radiation)

      Recruiting
      • Squamous Cell Carcinoma of Head and Neck
      • Pembrolizumab
      • +3 more
      • Chapel Hill, North Carolina
      • +1 more
      Oct 25, 2022

      Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

      Recruiting
      • Her-2 Negative Breast Cancer
      • HRR Gene Mutation
      • Guangzhou, Guangdong, China
        First Affiliated Hospital, Sun Yat-Sen University
      Mar 7, 2023